Modulation of lung reperfusion injury by nitric oxide: impact of inspired oxygen fraction

Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants

OBJECTIVES

Inhaled nitric oxide treatment for ventilated premature infants improves survival without bronchopulmonary dysplasia. However, there has been no information regarding possible effects of this therapy on oxidative stress. We hypothesized that inhaled nitric oxide therapy would not influence concentrations of plasma biomarkers of oxidative stress.

PATIENTS AND METHODS

As part of the Nitric Oxide Chronic Lung Disease Trial, we collected blood samples at specified intervals from a subpopulation of 100 infants of <1250 g birth weight who received inhaled nitric oxide (20 ppm, weaned to 2 ppm) or placebo gas for 24 days. Plasma was assayed for total protein and for 3-nitrotyrosine and carbonylation by using immunoassays.

RESULTS

The demographic characteristics and primary outcome for the infants were representative of the entire group of infants who were in the Nitric Oxide Chronic Lung Disease Trial. For all infants at baseline, before receiving study gas, the concentration of total protein was inversely correlated with the respiratory severity score, and plasma carbonyl was positively correlated with severity score, supporting an association between oxidative stress and severity of lung disease. Infants who survived without bronchopulmonary dysplasia had 30% lower protein carbonylation concentrations at study entry than those who had an adverse outcome. At each of 3 time points (1-10 days) during exposure to study gas, there were no significant differences between control and treated infants for concentrations of plasma protein, 3-nitrotyrosine, and carbonylation.

CONCLUSIONS

Inhaled nitric oxide treatment for premature infants who are at risk for bronchopulmonary dysplasia does not alter plasma biomarkers of oxidative stress, which supports the safety of this therapy.

Inhaled Nitric Oxide Does Not Prevent Pulmonary Edema After Lung Transplantation Measured By Lung Water Content

STUDY OBJECTIVE

In order to assess the effects of inhaled nitric oxide (iNO) in preventing early-onset lung edema from occurring after lung transplantation, we measured extravascular lung water (EVLW) in a group of lung transplant recipients who were at high risk for developing ischemia-reperfusion-induced lung injury.

DESIGN

Prospective, randomized study.

SETTINGS

Surgical ICU in a teaching hospital.

PATIENTS

Thirty double-lung transplant recipients.

INTERVENTIONS

Patients were randomized to receive or not receive 20 ppm iNO at the time of reperfusion (ie, before any occurrence of lung edema). In the NO group, iNO was then administered for a 12-h period. A double-dilution technique was used for the serial assessment of EVLW, intrathoracic blood volume, and cardiac index. Standard hemodynamic and pulmonary parameters were also recorded during the first 3 postoperative days.

MEASUREMENTS AND RESULTS

Patients who received iNO did not have a different lung water content compared to control subjects (p = 0.61 [by analysis of variance (ANOVA)]). Blood oxygenation (ie, Pao(2)/fraction of inspired oxygen [Fio(2)] ratio) did not differ between the two groups (p = 0.61 [by ANOVA]). In both groups, EVLW and Pao(2)/Fio(2) ratio dropped significantly over time, regardless of the use of iNO (p < 0.01 [by ANOVA]).

CONCLUSIONS

In the population studied, prophylactic iNO that was administered at 20 ppm had no effect on pulmonary edema formation and resolution following lung transplantation.

Lung preservation

Better understanding of the mechanisms of ischemia-reperfusion injury, improvement in the technique of lung preservation, and the recent introduction of a new preservation solution specifically developed for the lungs have helped to reduce the incidence of primary graft dysfunction after lung transplantation. Currently, the limitation in extending the ischemic time is more often related to the increasing use of non-ideal lung donors rather than to poor lung preservation. In this review, we have focused our attention on the experimental and clinical work performed to optimize the methods of lung preservation from the time of retrieval to the period of reperfusion after graft implantation.

Estudo da fração inspirada de oxigênio na isquemia-reperfusão pulmonar em ratos

OBJETIVO: Estudar o efeito das frações inspiradas de oxigênio (FiO2) a 0,21, 0,40 e 1,00 na isquemia-reperfusão pulmonar. MÉTODOS: Foram utilizados 40 ratos Wistar, distribuídos aleatoriamente em quatro grupos. O grupo I foi o controle e, nos grupos II, III e IV, os animais foram ventilados durante a isquemia-reperfusão com FiO2 a 0,21, 0,40 e 1,00 respectivamente. O modelo utilizado foi de isquemia-reperfusão normotérmica, in situ. O tempo de isquemia foi de 30 minutos e o de reperfusão, de 10 minutos. Como parâmetros de avaliação, utilizou-se a pressão arterial média sistêmica (PAM), a relação entre a pressão parcial de oxigênio e a fração inspirada de oxigênio (PO2/FiO2), a dosagem da glutationa reduzida (GSH) e das substâncias reativas ao ácido tiobarbitúrico (TBARS) no tecido pulmonar e a relação entre o peso pulmonar úmido e o peso pulmonar seco. RESULTADOS: Os resultados mostraram que a ventilação com FiO2 a 0,21, quando comparada à ventilação com FiO2 a 0,40 e 1,00, durante o período de isquemia-reperfusão, apresentou menor diminuição da PAM, melhor relação PO2/FiO2, maior valor na medida da GSH, menor produção das TBARS e menor formação de edema pulmonar. CONCLUSÃO: A ventilação com baixa FiO2 (0,21) mostrou melhores resultados quando comparada àquelas realizadas com FiO2 mais elevadas (0,40 e 1,00) na isquemia-reperfusão pulmonar.

Lung transplantation. Lung preservation

Over the past decade, improvements in the technique of lung preservation have led to significant reduction in the incidence of ischemia-reperfusion-induced lung injury after lung transplantation. The challenge remains to improve the number of donor lungs available for transplantation. While the number of patients on the waiting list is constantly increasing, only 10% to 30% of donor lungs are currently being used for transplantation. Hence, the development of new strategies to assess, repair, and improve the quality of the lungs could have a tremendous impact on the number of transplants performed. In addition, an improved understanding of the mechanisms involved in lung preservation might help elucidate the potential link between acute lung injury and chronic graft dysfunction. In the future, genetic analysis using novel technologies such as microarray analysis will help researchers determine which genes control the injury seen in the transplantation process. Hopefully, this information will provide new insights into the mechanisms of injury and reveal potential new strategies and targets for therapies to improve lung preservation.

Ischemia-reperfusion-induced lung injury

Ischemia-reperfusion-induced lung injury is characterized by nonspecific alveolar damage, lung edema, and hypoxemia occurring within 72 hours after lung transplantation. The most severe form may lead to primary graft failure and remains a significant cause of morbidity and mortality after lung transplantation. Over the past decade, better understanding of the mechanisms of ischemia-reperfusion injury, improvements in the technique of lung preservation, and the development of a new preservation solution specifically for the lung have been associated with a reduction in the incidence of primary graft failure from approximately 30 to 15% or less. Several strategies have also been introduced into clinical practice for the prevention and treatment of ischemia-reperfusion-induced lung injury with various degrees of success. However, only three randomized, double-blinded, placebo-controlled trials on ischemia-reperfusion-induced lung injury have been reported in the literature. In the future, the development of new agents and their application in prospective clinical trials are to be expected to prevent the occurrence of this potentially devastating complication and to further improve the success of lung transplantation.